Third HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide for relapsed acute leukemia – Bone Marrow Transplantation

Tachibana T, Matsumoto K, Tanaka M, Hagihara M, Motohashi K, Yamamoto W, et al. Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation. Leuk Lymphoma. 2017;58:1403–11. https://doi.org/10.1080/10428194.2016.1243678.

Article  PubMed  Google Scholar 

Rank A, Peczynski C, Labopin M, Stelljes M, Simand C, Helbig G, et al. Feasibility and outcomes of a third allogeneic hematopoietic stem cell transplantation: a retrospective analysis from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Transplant Cell Ther. 2021;27:408.e401–8.e406. https://doi.org/10.1016/j.jtct.2021.01.025.

Article  CAS  Google Scholar 

Kobayashi S, Kanda Y, Konuma T, Inamoto Y, Matsumoto K, Uchida N, et al. Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. Bone Marrow Transpl. 2022;57:43–50. https://doi.org/10.1038/s41409-021-01485-6.

Article  Google Scholar 

Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3:35–44. https://doi.org/10.1002/sim.4780030106.

Article  CAS  PubMed  Google Scholar 

Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhauser M, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31:3259–71. https://doi.org/10.1200/jco.2012.44.7961.

Article  PubMed  Google Scholar 

Konuma T, Kato S, Ooi J, Ebihara Y, Mochizuki S, Oiwa-Monna M, et al. Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT. Int J Hematol. 2015;101:392–7. https://doi.org/10.1007/s12185-015-1755-7.

Article  PubMed  Google Scholar 

Tischer J, Engel N, Fritsch S, Prevalsek D, Hubmann M, Schulz C, et al. Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transpl. 2014;49:895–901. https://doi.org/10.1038/bmt.2014.83.

Article  CAS  Google Scholar 

Imus PH, Blackford AL, Bettinotti M, Iglehart B, Dietrich A, Tucker N, et al. Major histocompatibility mismatch and donor choice for second allogeneic bone marrow transplantation. Biol Blood Marrow Transpl. 2017;23:1887–94. https://doi.org/10.1016/j.bbmt.2017.07.014.

Article  Google Scholar 

Rimando J, McCurdy SR, Luznik L. How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023;141:49–59. https://doi.org/10.1182/blood.2021015129

Article  CAS  PubMed  Google Scholar 

Sugita J. HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Int J Hematol. 2019;110:30–8. https://doi.org/10.1007/s12185-019-02660-8.

Article  CAS  PubMed  Google Scholar